Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 12/20 | 0.70 |
| ▸ | TOP2A | P11388 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | GAPDH | P04406 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Helioxanthin SCHEMBL2960321 | 1.00 | ALOX5 (0.70) | ALOX5TOP2AKDM4EALDH1A1MAPT | |
| SCHEMBL7654491 | 0.91 | ALOX5 (0.61) | ALOX5TOP2A | |
| SCHEMBL8084873 | 0.89 | ALOX5 (0.64) | ALOX5TOP2A | |
| SCHEMBL7655746 | 0.88 | ALOX5 (0.54) | ALOX5TOP2AKDM4EMEN1KMT2A | |
| SCHEMBL8080529 | 0.88 | ALOX5 (0.54) | ALOX5TOP2AKDM4EALDH1A1MAPT | |
| SCHEMBL7656932 | 0.88 | ALOX5 (0.54) | ALOX5TOP2AKDM4E | |
| SCHEMBL8084991 | 0.86 | TOP2A (0.70) | ALOX5TOP2AKDM4EALDH1A1MAPT | |
| SCHEMBL7656265 | 0.85 | ALOX5 (0.60) | ALOX5TOP2AKDM4EALDH1A1MAPT | |
| SCHEMBL8082006 | 0.85 | ALOX5 (0.51) | ALOX5TOP2AALDH1A1MEN1KMT2A | |
| SCHEMBL19367502 | 0.83 | TOP2A (0.58) | ALOX5TOP2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | ALOX5 1745/4885TOP2A 2497/4885KDM4E 4329/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | ALOX5 1745/4885TOP2A 2497/4885KDM4E 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.